Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 5/2015

01-10-2015 | Original Paper

Prognostic value of cytokeratin-7 mRNA expression in peripheral whole blood of advanced lung adenocarcinoma patients

Authors: Ana Koren, Eva Sodja, Matija Rijavec, Mojca Jez, Viljem Kovac, Peter Korosec, Tanja Cufer

Published in: Cellular Oncology | Issue 5/2015

Login to get access

Abstract

Background

The rarity of circulating tumour cells (CTCs) in peripheral blood requires the application of sensitive techniques for their detection. The aim of our study was to (i) first determine the sensitivity of cytokeratin-7 (KRT7) mRNA expression levels for the molecular detection of CTCs using spiked-in lung adenocarcinoma (AC)-derived A549 cells and (ii) evaluate the impact of KRT7 mRNA expression in peripheral whole blood on the response to treatment and prognosis of patients with advanced lung AC who were treated with first-line platinum-based chemotherapy.

Methods

A549 cells were micro-manipulated before being spiked into whole blood samples obtained from healthy donors. Additionally, whole blood samples from 65 lung AC patients were collected in PAXgene blood tubes before the start of first-line platinum-based chemotherapy. KRT7 mRNA expression was measured using RT-qPCR.

Results

Through the spike-in experiment we found that it is feasible to detect a single A549 tumour cell in 2.5 ml whole blood and that the KRT7 mRNA levels were linearly correlated with the number of spiked-in tumour cells with a high reproducibility. In lung AC patients, no significant differences in response rate to chemotherapy, progression-free survival or overall survival and KRT7 mRNA levels were found.

Conclusions

Our data show that KRT7 mRNA expression measured by RT-qPCR serves as a sensitive approach for the molecular detection of KRT7-positive CTC-resembling A549 cells in peripheral whole blood. The KRT7 mRNA levels measured were not significantly associated with the response to chemotherapy or the survival of patients with advanced lung AC. Additional studies are required to establish the possible clinical significance of KRT7 mRNA expression in whole blood after chemotherapy.
Appendix
Available only for authorised users
Literature
1.
J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin, D. Forman, F. Bray, in GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11 [Internet]. Lyon, International Agency for Research on Cancer. http://​globocan.​iarc.​fr Accessed 16 November 2014
2.
N. Peled, M.W. Wynes, N. Ikeda, T. Ohira, K. Yoshida, J. Qian, M. Ilouze, R. Brenner, Y. Kato, C. Mascaux, F.R. Hirsch, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell. Oncol. 36, 277–88 (2013)CrossRef
3.
S.H. Ahn, E.H. Jeong, T.G. Lee, S.Y. Kim, H.R. Kim, C.H. Kim, Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells. Cell. Oncol. 37, 377–386 (2014)CrossRef
4.
P. Ulivi, R. Silvestrini, Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell. Oncol. 36, 439–448 (2013)CrossRef
5.
L.G. Collins, C. Haines, R. Perkel, R.E. Enck, Lung cancer: diagnosis and management. Am. Fam. Physician 75, 56–63 (2007)PubMed
6.
T. Cufer, L. Knez, Update on systemic therapy of advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 14, 1189–1203 (2014)CrossRefPubMed
7.
B. Kubuschok, B. Passlick, J.R. Izbicki, O. Thetter, K. Pantel, Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J. Clin. Oncol. 17, 19–24 (1999)PubMed
8.
V. Hofman, C. Bonnetaud, M.I. Ilie, P. Vielh, J.M. Vignaud, J.F. Fléjou, S. Lantuejoul, E. Piaton, N. Mourad, C. Butori, E. Selva, M. Poudenx, S. Sibon, S. Kelhef, N. Vénissac, J.P. Jais, J. Mouroux, T.J. Molina, P. Hofman, Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin. Cancer Res. 17, 827–835 (2011)CrossRefPubMed
9.
M.G. Krebs, J.M. Hou, R. Sloane, L. Lancashire, L. Priest, D. Nonaka, T.H. Ward, A. Backen, G. Clack, A. Hughes, M. Ranson, F.H. Blackhall, C. Dive, Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J. Thorac. Oncol. 7, 306–315 (2012)CrossRefPubMed
10.
T.J.N. Hiltermann, M.M. Pore, A. van den Berg, W. Timens, H.M. Boezen, J.J. Liesker, J.H. Schouwink, W.J. Wijnands, G.S. Kerner, F.A. Kruyt, H. Tissing, A.G. Tibbe, L.W. Terstappen, H.J. Groen, Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 23, 2937–2942 (2012)CrossRefPubMed
11.
W.J. Allard, J. Matera, M.C. Miller, M. Repollet, M.C. Connelly, C. Rao, A.G. Tibbe, J.W. Uhr, L.W. Terstappen, Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897–6904 (2004)CrossRefPubMed
12.
M. Cristofanilli, G.T. Budd, M.J. Ellis, A. Stopeck, J. Matera, M.C. Miller, J.M. Reuben, G.V. Doyle, W.J. Allard, L.W. Terstappen, D.F. Hayes, Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781–791 (2004)CrossRefPubMed
13.
E.A. Punnoose, S. Atwal, W. Liu, R. Raja, B.M. Fine, B.G. Hughes, R.J. Hicks, G.M. Hampton, L.C. Amler, A. Pirzkall, M.R. Lackner, Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18, 2391–2401 (2012)CrossRefPubMed
14.
O. Hoffmann, E. Solomayer, S. Kuemmel, M. Hahn, S. Kasimir-Bauer, R. Kimmig, D. Wallwiener, T. Fehm, Does primary systemic therapy erradicate disseminated and circulating tumor cells? Cancer Res. 69, 3001–3001 (2009)CrossRef
15.
L.H. Broersen, G.W. van Pelt, R.A.E.M. Tollenaar, W.E. Mesker, Clinical application of circulating tumor cells in breast cancer. Cell. Oncol. 37, 9–15 (2014)CrossRef
16.
M.J. Kim, N.Y. Choi, E.K. Lee, M.S. Kang, Identification of novel markers that outperform EpCAM in quantifying circulating tumor cells. Cell. Oncol. 37, 235–243 (2014)CrossRef
17.
G. Vona, A. Sabile, M. Louha, V. Sitruk, S. Romana, K. Schütze, F. Capron, D. Franco, M. Pazzagli, M. Vekemans, B. Lacour, C. Bréchot, P. Paterlini-Bréchot, Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am. J. Pathol. 156, 57–63 (2000)PubMedCentralCrossRefPubMed
18.
S. Nagrath, L.V. Sequist, S. Maheswaran, D.W. Bell, D. Irimia, L. Ulkus, M.R. Smith, E.L. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U.J. Balis, R.G. Tompkins, D.A. Haber, M. Toner, Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239 (2007)PubMedCentralCrossRefPubMed
19.
R.T. Krivacic, A. Ladanyi, D.N. Curry, H.B. Hsieh, P. Kuhn, D.E. Bergsrud, J.F. Kepros, T. Barbera, M.Y. Ho, L.B. Chen, R.A. Lerner, R.H. Bruce, A rare-cell detector for cancer. Proc. Natl. Acad. Sci. U. S. A. 10, 10501–10504 (2004)CrossRef
20.
T. Nolan, R.E. Hands, S.A. Austin, Quantification of mRNA using real-time RT-PCR. Nat. Protoc. 1, 1559–1582 (2006)CrossRefPubMed
21.
L. Rainen, U. Oelmueller, S. Jurgensen, R. Wyrich, C. Ballas, J. Schram, C. Herdman, D. Bankaitis-Davis, N. Nicholls, D. Trollinger, V. Tryon, Stabilization of mRNA expression in whole blood samples. Clin. Chem. 48, 1883–1890 (2002)PubMed
22.
A.E. Ring, L. Zabaglo, M.G. Ormerod, I.E. Smith, M. Dowsett, Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br. J. Cancer 92, 906–912 (2005)PubMedCentralCrossRefPubMed
23.
R.A. Ghossein, S. Bhattacharya, R. Rosai, Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin. Cancer Res. 5, 1950–1960 (1999)PubMed
24.
N.B. Tsui, E.K. Ng, Y.M. Lo, Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin. Chem. 48, 1647–1653 (2002)PubMed
25.
E. Saloustros, M. Perraki, S. Apostolaki, G. Kallergi, A. Xyrafas, K. Kalbakis, S. Agelaki, A. Kalykaki, V. Georgoulias, D. Mavroudis, Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res. 13, R60 (2011)PubMedCentralCrossRefPubMed
26.
P. Chu, E. Wu, L.M. Weiss, Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 13, 962–972 (2000)CrossRefPubMed
27.
D.C. Chhieng, J.F. Cangiarella, M.F. Zakowski, S. Goswami, J.M. Cohen, H.T. Yee, Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer Cytopathol. 93, 330–336 (2001)CrossRef
28.
O. Arrieta, B. Pineda, S. Muñiz-Hernández, D. Flores, G. Ordóñez, J.R. Borbolla-Escoboza, D. Orta, Molecular detection and prognostic value of epithelial markers mRNA expression in peripheral blood of advanced non-small cell lung cancer patients. Cancer Biomark. 14, 215–223 (2014)PubMed
29.
D.G. Altman, L.M. McShane, W. Sauerbrei, S.E. Taube, Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 9, e1001216 (2012)PubMedCentralCrossRefPubMed
30.
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009)CrossRefPubMed
31.
M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, E.T. McFadden, P.P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649–655 (1982)CrossRefPubMed
32.
K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25, 402–408 (2001)CrossRefPubMed
33.
I.H. Al-Zahrani, The value of immunohistochemical expression of TTF-1, CK7 and CK20 in the diagnosis of primary and secondary lung carcinomas. Saudi Med. J. 29, 957–961 (2008)PubMed
34.
S. Paget, The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 8, 98–101 (1989)PubMed
35.
Y. Liu, J. Qian, J.G. Feng, H.X. Ju, Y.P. Zhu, H.Y. Feng, D.C. Li, Detection of circulating tumor cells in peripheral blood of colorectal cancer patients without distant organ metastases. Cell. Oncol. 36, 43–53 (2013)CrossRef
36.
J. Wang, J. Huang, K. Wang, J. Xu, J. Huang, T. Zhang, Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PLoS One 8, e78070 (2013)PubMedCentralCrossRefPubMed
37.
E. Borgen, B. Naume, J.M. Nesland, G. Kvalheim, K. Beiske, O. Fodstad, I. Diel, E.F. Solomayer, P. Theocharous, R.C. Coombes, B.M. Smith, E. Wunder, J.P. Marolleau, J. Garcia, K. Pantel, Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1, 377–388 (1999)CrossRefPubMed
38.
M.G. Krebs, R. Sloane, L. Priest, L. Lancashire, J. Hou, A. Greystoke, T.H. Ward, R. Ferraldeschi, A. Hughes, G. Clack, M. Ranson, C. Dive, F.H. Blackhall, Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 29, 1556–1563 (2011)CrossRefPubMed
39.
A. Stathopoulou, Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20, 3404–3412 (2002)CrossRefPubMed
40.
T.A. Masuda, A. Kataoka, S. Ohno, S. Murakami, K. Mimori, T. Utsunomiya, H. Inoue, S. Tsutsui, J. Kinoshita, N. Masuda, N. Moriyama, M. Mori, Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. Int. J. Oncol. 26, 721–730 (2005)PubMed
41.
S.O. Yoon, Y.T. Kim, K.C. Jung, Y.K. Jeon, B.H. Kim, C.W. Kim, TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer 71, 209–216 (2011)CrossRefPubMed
42.
K. Peck, Y.P. Sher, J.Y. Shih, S.R. Roffler, C.W. Wu, P.C. Yang, Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res. 58, 2761–2765 (1998)PubMed
43.
W.F. Zhu, J. Li, L.C. Yu, Y. Wu, X.P. Tang, Y.M. Hu, Y.C. Chen, Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients. Tumor Biol. 35, 1211–1219 (2013)CrossRef
44.
T.F. Chen, G.L. Jiang, X.L. Fu, L.J. Wang, H. Qian, K.L. Wu, S. Zhao, CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 56, 105–114 (2007)CrossRefPubMed
45.
S.A. Joosse, J. Hannemann, J. Spötter, A. Bauche, A. Andreas, V. Müller, K. Pantel, Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin. Cancer Res. 18, 993–1003 (2012)CrossRefPubMed
46.
N. Xenidis, I. Vlachonikolis, D. Mavroudis, M. Perraki, A. Stathopoulou, N. Malamos, C. Kouroussis, S. Kakolyris, S. Apostolaki, N. Vardakis, E. Lianidou, V. Georgoulias, Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann. Oncol. 14, 849–855 (2003)CrossRefPubMed
47.
A.M. Sieuwerts, J. Kraan, J. Bolt-de Vries, P. van der Spoel, B. Mostert, J.W. Martens, J.W. Gratama, S. Sleijfer, J.A. Foekens, Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res. Treat. 118, 455–468 (2009)CrossRefPubMed
48.
J.P. Thiery, J.P. Sleeman, Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131–142 (2006)CrossRefPubMed
49.
M. Perán, J.A. Marchal, M.A. García, J. Kenyon, D. Tosh, In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation. Cell. Oncol. 36, 289–301 (2013)CrossRef
50.
A. Koren, H. Motaln, T. Cufer, Lung cancer stem cells: a biological and clinical perspective. Cell. Oncol. 36, 265–275 (2013)CrossRef
51.
M. Sabbah, S. Emami, G. Redeuilh, S. Julien, G. Prévost, A. Zimber, R. Ouelaa, M. Bracke, O. De Wever, C. Gespach, Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. 11, 123–151 (2008)CrossRefPubMed
52.
B. Willipinski-Stapelfeldt, S. Riethdorf, V. Assmann, U. Woelfle, T. Rau, G. Sauter, J. Heukeshoven, K. Pantel, Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin. Cancer Res. 11, 8006–8014 (2005)CrossRefPubMed
53.
A.J. Armstrong, M.S. Marengo, S. Oltean, G. Kemeny, R.L. Bitting, J.D. Turnbull, C.I. Herold, P.K. Marcom, D.J. George, M.A. Garcia-Blanco, Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 9, 997–1007 (2011)PubMedCentralCrossRefPubMed
54.
M. Yu, A. Bardia, B.S. Wittner, S.L. Stott, M.E. Smas, D.T. Ting, S.J. Isakoff, J.C. Ciciliano, M.N. Wells, A.M. Shah, K.F. Concannon, M.C. Donaldson, L.V. Sequist, E. Brachtel, D. Sgroi, J. Baselga, S. Ramaswamy, M. Toner, D.A. Haber, S. Maheswaran, Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013)PubMedCentralCrossRefPubMed
55.
A. Lecharpentier, P. Vielh, P. Perez-Moreno, D. Planchard, J.C. Soria, F. Farace, Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br. J. Cancer 105, 1338–1341 (2011)PubMedCentralCrossRefPubMed
56.
A. Gradilone, C. Raimondi, C. Nicolazzo, A. Petracca, O. Gandini, B. Vincenzi, G. Naso, A.M. Aglianò, E. Cortesi, P. Gazzaniga, Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J. Cell. Mol. Med. 15, 1066–1070 (2011)PubMedCentralCrossRefPubMed
Metadata
Title
Prognostic value of cytokeratin-7 mRNA expression in peripheral whole blood of advanced lung adenocarcinoma patients
Authors
Ana Koren
Eva Sodja
Matija Rijavec
Mojca Jez
Viljem Kovac
Peter Korosec
Tanja Cufer
Publication date
01-10-2015
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 5/2015
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-015-0238-4

Other articles of this Issue 5/2015

Cellular Oncology 5/2015 Go to the issue

Original Paper

Anti-tumor effect of emodin on gynecological cancer cells

Original Paper

MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells

Original Paper

Metformin and epithelial ovarian cancer therapeutics

Original Paper

Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system

Original Paper

Methylation biomarkers for pleomorphic lobular breast cancer - a short report

Review

NF-κB signaling in cancer stem cells: a promising therapeutic target?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits